journal article Oct 01, 2015

Alcohol enhances the psychostimulant and conditioning effects of mephedrone in adolescent mice; postulation of unique roles of D3receptors and BDNF in place preference acquisition

British Journal of Pharmacology Vol. 172 No. 20 pp. 4970-4984 · Wiley
View at Publisher Save 10.1111/bph.13266
Abstract
Background and PurposeThe psychostimulant mephedrone is often consumed in combination with alcohol (EtOH). This kind of drug consumption during adolescence is a matter of concern.Experimental ApproachWe studied, in adolescent CD‐1 mice, whether EtOH could enhance the psychostimulant (locomotor acivity) and rewarding [conditioned place preference (CPP)] effects of mephedrone. We also determined the transcriptional changes associated with a conditioning treatment with these drugs.Key ResultsMephedrone (10 mg·kg−1) increased locomotor activity, which was further enhanced by 40% when combined with EtOH (1 g·kg−1). This enhancement was blocked by haloperidol. Furthermore, mephedrone (25 mg·kg−1) induced CPP, which increased by 70% when administered with a dose of EtOH that was not conditioning by itself (0.75 g·kg−1). There was enhanced expression of the D3dopamine receptor mRNA (Drd3) andArpc5in all drug‐treated groups. The D3receptor antagonist SB‐277011A and the BDNF receptor antagonist ANA‐12 completely prevented CPP as well as the increases inDrd3in all groups. Accordingly, increased expression of BDNF mRNA in medial prefrontal cortex was detected at 2 and 4 h after mephedrone administration.Conclusions and ImplicationsIf translated to humans, the enhancement of mephedrone effects by ethanol could result in increased abuse liability. D3receptors and BDNF play a key role in the establishment of CPP by mephedrone, although an accompanying increase in other synaptic plasticity‐related genes may also be necessary.
Topics

No keywords indexed for this article. Browse by subject →

References
67
[10]
Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice

Maxime Cazorla, Joël Prémont, Andre Mann et al.

Journal of Clinical Investigation 10.1172/jci43992
[17]
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report (2010). ISBN/ISSN: 978-92-9168-432-8. Available at:www.emcdda.europa.eu/publications/annual-report/2010(accessed 9/3/2015).
[32]
Levant B "The D3 dopamine receptor: neurobiology and potential clinical relevance" Pharmacol Rev (1997) 10.1016/s0031-6997(24)01327-9
[36]
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Kenneth J. Livak, Thomas D. Schmittgen

Methods 10.1006/meth.2001.1262
[42]
Measham F "Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition" DrugsAlcohol Today (2010)
[48]
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

Adam J. Pawson, Joanna L. Sharman, Helen E. Benson et al.

Nucleic Acids Research 10.1093/nar/gkt1143
[50]
Dose translation from animal to human studies revisited

Shannon Reagan‐Shaw, Minakshi Nihal, Nihal Ahmad

The FASEB Journal 10.1096/fj.07-9574lsf

Showing 50 of 67 references

Related

You May Also Like